Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS) from a hold rating to a sell rating in a research note released on Friday morning.

Several other research analysts also recently commented on ABUS. JMP Securities boosted their target price on Arbutus Biopharma from $4.00 to $5.00 and gave the stock a market outperform rating in a report on Friday. HC Wainwright reissued a buy rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Thursday, June 6th. Finally, Chardan Capital reissued a buy rating and issued a $4.00 target price on shares of Arbutus Biopharma in a report on Wednesday, June 5th.

Arbutus Biopharma Trading Down 3.1 %

ABUS stock opened at $3.62 on Friday. Arbutus Biopharma has a 1-year low of $1.69 and a 1-year high of $3.98. The firm has a market cap of $683.17 million, a P/E ratio of -7.77 and a beta of 1.96. The business’s 50 day moving average is $3.39 and its 200-day moving average is $2.97.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 68.02%. The company had revenue of $1.73 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Sell-side analysts forecast that Arbutus Biopharma will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in Arbutus Biopharma during the 2nd quarter worth $34,000. Walleye Trading LLC acquired a new position in shares of Arbutus Biopharma in the 1st quarter valued at $36,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Arbutus Biopharma by 351.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 15,104 shares during the period. PFG Investments LLC acquired a new position in shares of Arbutus Biopharma in the 1st quarter valued at $50,000. Finally, Premier Path Wealth Partners LLC lifted its stake in shares of Arbutus Biopharma by 37.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 30,500 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 8,300 shares during the period. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.